Quantitative polymerase chain reaction (QPCR) for cytomegalovirus (CMV) is emerging as the preferred screening method for detection of CMV viremia in patients following allogeneic bone marrow and peripheral blood stem cell transplant. However, there are currently no universally accepted QPCR treatment thresholds at which to start preemptive therapy. We report here results of a pre-emptive therapy strategy using ganciclovir (GCV) 5 mg/kg initiated once daily (ODG) delayed till a threshold CMV load of X10 000 copies/ml whole blood in clinically stable patients. Sixty-nine at risk patients underwent allogeneic stem cell transplant. 48/69 (70%) patients had an initial episode of CMV viremia. 5/48 (10%) cleared viremia without requiring treatment. 28/43 (65%) patients requiring treatment initiated treatment with ODG. 17/28 (61%) patients successfully cleared CMV viremia on ODG, 10/28 (36%) patients required dose escalation to twice daily GCV for increasing viral loads. There were two cases of CMV disease (colitis) and no deaths due to CMV disease in patients initiating treatment with ODG. We conclude delaying pre-emptive therapy with ODG until whole blood QPCRX10 000 copies/ ml is a safe and effective strategy for CMV viremia after allogeneic stem cell transplant in clinically stable patients.
Introduction
Cytomegalovirus (CMV) remains a major cause of morbidity and mortality following allogeneic bone marrow or peripheral blood stem cell transplantation. A patient is considered to be at risk for reactivation of CMV when either the donor or recipient is CMV seropositive. Prior to prophylactic or pre-emptive use of antiviral agents, CMV disease occurred in 15-45% of at risk patients and carried a high mortality rate. 1, 2 While both prophylactic and pre-emptive treatment strategies have decreased the mortality associated with CMV, most centers use a pre-emptive treatment strategy using ganciclovir (GCV) or foscarnet to prevent the development of CMV disease to avoid the hematologic toxicity associated with prophylactic GCV treatment. [3] [4] [5] [6] The surveillance modalities used to detect CMV viremia have included viral culture, shell vial assays, antigenemia assays and polymerase chain reaction (PCR). [7] [8] [9] [10] [11] In some studies, the reported incidence of CMV viremia is higher in patients screened by CMV PCR compared with antigenemia or shell vial assays reflecting the increased sensitivity of PCR assays compared with other screening methods. 11, 12 There is concern that some patients in whom CMV is detected by PCR may receive unnecessary pre-emptive therapy on account of increased sensitivity of this testing modality. The recent development of quantitative PCR (QPCR) for CMV offers the possibility of developing a threshold level for initiating treatment that would minimize unnecessary exposure to antiviral agents. [9] [10] [11] 13, 14 However, there is currently no agreement of what type of blood specimen should be tested (whole blood, plasma, leukocyte preparation) nor is there agreement on the optimal threshold level for initiating pre-emptive therapy.
Most centers initiate pre-emptive therapy with GCV (5 mg/kg) twice daily for patients who develop CMV viremia. We have previously shown GCV 5 mg/kg initiated once daily (ODG) to be a strategy for pre-emptive therapy that is effective and associated with minimal hematologic toxicity. 15 We now extend our pre-emptive therapy experience with ODG using a quantitative CMV PCR strategy to delay the initiation of ODG until a threshold CMV load of X10 000 copies/ml whole blood in clinically stable patients. Table 1 . Peripheral blood stem cell products were infused without T-cell depletion. All patients received acyclovir for herpes simplex virus and trimethoprim-sulfamethoxazole for pneumocystis carinii prophylaxis until immunosuppression was discontinued. Prophylaxis for fungal infections was left to the discretion of the treating physician.
Patients and methods

Patient population
Quantitative CMV PCR and UL-97mutation assay All patients were routinely monitored for CMV viremia weekly from engraftment to day 100 and every 2 weeks thereafter with quantitative CMV PCR. Quantitative CMV PCR was performed as described previously. 16 Briefly, whole-blood samples were processed by the MagNa Pure automated extractor using the MagNa Pure LC Total Nucleic Acid Isolation Kit. The LightCycler real-time PCR instrument was used to amplify, detect, and quantify CMV DNA from whole-blood samples, using a 5 0 exonuclease ('Taqman') assay. Primer sequences were: sense 5 0 -GCTGA CGCGTTTGGTCAT-3 0 and antisense 5 0 -ACGATTCAC GGAGCACCAG-3 0 . The probe sequence was 5 0 -FAM-TCGGCGGATCACCACGTTCG-TAMRA-3 0 . For quantitation, a standard curve was constructed based on testing serial dilutions (corresponding to 2.0 Â 10 3 -1.25 Â 10 6 genome copies per ml) of a reference standard of purified CMV genomes (Advanced Biotechnologies Inc., Columbia, MD, USA). The lower limit of detection of the assay is 200 genome copies per ml. As they were beneath the lower limit of the standard curve, positive samples with values less than 2.0 Â 10 3 genome copies per ml were reported as 'positive, unable to quantitate'. Each assay run also contained an 'inter-run standard', and the assay run was considered acceptable only if the calculated value of the inter-run standard was within 2 standard deviations of the mean calculated from at least 30 previous determinations. To assess for the emergence of GCV resistance, a segment of the UL97 gene was amplified directly from the patient's whole blood, and sequenced to detect mutations known to be associated with GCV resistance. This was carried out on all patients who failed to show a one log decline within 1 week of therapy with GCV.
Pre-emptive therapy
We elected to initiate treatment with ODG for 21 days using a threshold whole-blood PCR X10 000 copies/ml in clinically stable patients. Patients with concurrent active Grade III-IV GVHD, development/suspicion of CMV disease prior to or concurrent with first detection of CMV viremia by PCR were treated with GCV 5 mg/kg twice daily or foscarnet. CMV PCR assays during the 21-day course of GCV were required to be repeated weekly. Clinically stable patients with positive CMV PCR o10 000 copies/ml whole blood were observed without treatment. Dose escalation to twice daily GCV was permitted for increasing whole-blood PCR on ODG. Patients were considered to have cleared CMV viremia when their CMV viral load had declined to unquantifiable levels (o2000 copies/ml whole blood). Recurrent episodes of viremia were re-treated according to the discretion of the treating physician.
Definition of CMV disease CMV pneumonia is defined as the presence of interstitial infiltrates on chest radiograph accompanied by a histologic demonstration of CMV on lung biopsy or a positive CMV culture on bronchoalveolar fluid. A diagnosis of CMV colitis was based on clinical and endoscopic signs of colitis, together with histologic demonstration of CMV inclusions or positive culture for CMV from tissue samples obtained at biopsy.
Results
CMV viremia
The mean age (range) of patients was 46.5 (20-67) years. Patients were followed for a minimum of 120 days post transplant or until death with a mean follow-up of 213(6-478) days. A total of 69 patients were at risk for CMV reactivation (donor or recipient CMV seropositive prior to transplant). One or more episodes of CMV viremia (whole blood CMV PCR X200 copies/ml) occurred in 48/69 (70%) of patients at risk for CMV viremia (Table 2) . A total of 5/48 (10%) patients cleared CMV viremia without treatment and never experienced a recurrent episode of CMV viremia requiring treatment. These five patients had viral loads ranging 200-4268 copies/ml detected 3-90 days post transplant. In 20/48 (42%) patients, serial CMV viral loads increased to X10 000 copies/ml and patients received preemptive therapy. In 23/48 (48%) patients the initial CMV viral load was X10 000 copies/ml. The onset of CMV viremia (CMV viral load X200 copies/ml) in the 48 viremic patients occurred a median of 36 (À3 to 308) days post transplant. CMV viremia with X10 000 copies/ml in this group of 48 patients occurred at a median of 41 (À3-308) days post transplant. The onset of CMV viremia (CMV viral load X200 copies/ml) in patients receiving ODG occurred a median of 38 (19-62) days post transplant. CMV viremia with X10 000 copies/ml in the cohort treated with ODG occurred a median of 41 (27-196) days post transplant.
Results of pre-emptive therapy Overall, 43/69 (62%) of at risk patients received preemptive therapy for CMV viremia ( 
Recurrent viremia
One or more episodes of recurrent viremia (CMV viral load X10 000 copies/ml) occurred in 12/28 (43%) patients, who began therapy with ODG, a mean of 109 (54-247) days post transplant (Table 3) . Episodes of late CMV reactivation were not uncommon in patients continued on immunosuppressive therapy.
CMV disease
Overall, there were 4 (6%) cases of CMV disease in the entire cohort of 69 patients at risk for CMV viremia. Two of these patients initiated therapy with GCV 5 mg/kg twice daily due to acute illness. These patients developed CMV pneumonitis, which contributed to their deaths. Both these patients who died of CMV pneumonia had viral loads of X10 000 on the initial positive PCR. Two patients who began therapy with ODG developed CMV colitis, one during the initial episode of viremia and one during a recurrence 195 days post transplant. Both were successfully treated. There were no deaths due to CMV disease in patients initiating therapy with ODG.
Toxicity
The mean absolute neutrophil count (ANC) of patients prior to starting ODG was 6940/ml (range 1344-17028/ml). The mean ANC on completion of a 21-day course of ODG was 3684/ml (range 6-7200/ml). One patient exhibited a decline in ANC from 2820 to 671/ml and was changed to foscarnet after 9 days of therapy. Two patients received myeloid growth factors. One patient was treated with G-CSF for an ANC, which declined from 9400 to 1131/ml 10 days after the start of ODG. One patient developed graft failure (ANC 6/ml) and was subsequently treated with a second transplant. This patient had a declining ANC prior to the initiation of ODG.
Discussion
The reported incidence of CMV viremia in at risk patients following bone marrow or peripheral blood stem cell transplant can vary depending on the monitoring strategy. PCR is a more sensitive test of CMV viremia than shell vial or antigenemia assays and can result in a larger number of patients testing positive for CMV viremia. Studies comparing PCR monitoring with antigenemia or shell vial assays have shown a higher incidence of CMV viremia in patients monitored by PCR. [10] [11] [12] [13] 17 Results of some of these studies are summarized in Table 5 .
More recently, quantitative CMV PCR has emerged as a method to monitor CMV viremia in transplant patients. [9] [10] [11] 14, 18, 19 Internal controls at our institution have shown CMV shell vial cultures are consistently negative at CMV viral loads less than 15 000 copies/ml whole blood. In our laboratory, quantitative CMV PCR is more sensitive than qualitative CMV PCR. Half of the qualitative CMV PCR assays are negative at less than 4000 copies/ml whole blood by quantitative CMV PCR.
Although CMV is highly associated with leukocytes, CMV DNA can also be found in plasma when the virus is undergoing active viral replication. 16 Inhomogeneity of leukocyte lysates can lead to variability and inaccuracies in results. Inconsistencies in procedures for storage of blood samples and separation of plasma from whole blood can lead to artificially increased CMV viral loads secondary to lysis of cells. 16 For these reasons we prefer to use whole blood over leukocyte lysates or plasma for CMV viral load detection.
There are currently no criteria for standard treatment threshold for quantitative CMV PCR monitoring strategies. Some published studies have attempted to correlate CMV viral loads with the incidence of CMV disease in both bone marrow as well as solid organ transplant patients. These studies are summarized in Table 6 . While there was considerable variation in viral loads measured, all of these studies found patients with CMV disease had higher initial or peak viral loads on average than patients who did not develop CMV disease. Emery found both initial viral load as well as rate of increase of viral load were risk factors for development of CMV disease and calculated probabilities of developing CMV disease based on these parameters in their patient cohort. 20 
Table 5
Reported incidence of CMV viremia by monitoring strategy Currently, there are no criteria for initiation of preemptive therapy of CMV viremia using a quantitative CMV PCR monitoring strategy. Potentially, CMV viremia can be monitored and pre-emptive treatment can be safely withheld in patients with positive CMV PCR assays until the viral load reaches a threshold value. We chose to initiate pre-emptive therapy in patients with a CMV viral load X10 000 copies/ml of whole blood. To our knowledge, this is the first study to report a pre-emptive therapy strategy for CMV viremia based on initiating therapy after a threshold viral load is reached. Using this strategy we found that 20% of patients with an initial viral load o10 000 copies/ml whole blood cleared CMV viremia without treatment.
We have previously evaluated the efficacy of ODG as pre-emptive treatment for CMV viremia and found it to be effective and better tolerated than twice daily doses. 15 In the current series, we delayed the initiation of ODG until a threshold CMV load of X10 000 copies/ml whole blood in 28 clinically stable patients. Ten of these patients (36%) required a dose increase to GCV 5 mg/kg twice daily for increasing viral loads. This finding is similar to the incidence of dose escalation on ODG reported elsewhere in which 41% of patients initiated on ODG required dose escalation to twice daily for increasing viral loads. 10 In our laboratory, viral loads between 200-2000 copies/ml are considered positive but not quantifiable. Overall, 93% of patients starting treatment with ODG cleared CMV viremia (whole blood CMV PCR o2000 copies/ml) by 5 weeks of initiation of treatment.
Among all patients starting treatment with ODG, 32% cleared CMV viremia at 2 weeks of therapy. Among patients who completed ODG treatment, 57% cleared viremia by 2 weeks of therapy. This result compares favorably with rates of clearance of viremia reported elsewhere for patients initiated on treatment with conventional doses of GCV 5 mg/kg BID in which 52-61% of patients have been reported to clear CMV viremia after 2 weeks of therapy using PCR based surveillance strategies. 11, 21 Theoretically, the use of ODG may contribute to the emergence of resistant strains of CMV. Therefore, a mutation assay for the UL97 gene was performed on all patients with a rise in CMV copy number while on therapy with ODG. However, no patient had evidence of emergence of viral resistance by UL-97 gene mutation analysis. One or more episodes of recurrent viremia were seen in 43% (12/28) patients initiated on therapy with ODG. Rates of recurrent viremia employing GCV 5 mg/kg BID induction therapy have been reported to vary from 28 to 82%. 9, 12, 13, 21, 22 CMV disease was seen in 4/69 (6%) of our at risk patients. Incidence of CMV disease from 0 to 20% have been reported in previous studies in which patients were treated with pre-emptive therapy. 4, 6, 9, 12, 13, 23 Among our patients initiated on therapy with ODG, CMV disease (colitis) was seen in 2/28 (7%) patients. These patients were both successfully treated. There were no deaths due to CMV disease in patients treated with ODG.
We have previously reported on the low incidence of neutropenia using ODG. 15 The incidence of neutropenia was also low in the present cohort of patients as well. One patient required a treatment change to foscarnet and one patient required growth factor support secondary to declining ANC related to GCV.
In conclusion, delaying treatment with ODG as initial pre-emptive therapy until whole-blood PCR X10 000 copies/ml is a safe and effective treatment strategy for CMV viremia in clinically stable patients after allogeneic stem cell transplantation. This strategy reduces over treatment of patients. The incidence of neutropenia is low.
